Raleigh, NC – According to filings with the U.S. Securities and Exchange Commission, Bryn Pharma is raising $15,000,000.00 in new funding. Sources indicate as part of senior management President, Steven Hartman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bryn Pharma
Bryn Pharma is a privately held pharmaceutical company based in North Carolina. Primary focus is on the development and commercialization of innovative allergy products for the management of anaphylaxis. The mission of Bryn Pharma is to empower patients with a life-saving device that is small enough to comfortably fit in your pocket and easy to use in the event of an anaphylactic attack. Our intranasal delivery system will be an exciting alternative to epinephrine auto-injectors providing patients a needle-free option that is easy to use, portable, and affordable.

To learn more about Bryn Pharma, visit http://www.brynpharma.com/

Contact:
Steven Hartman, President
310-869-2204
shartman@brynpharma.com
https://www.linkedin.com/in/steven-hartman-025960113/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved